Clin2
NCT05590455Possibly a fitRecruiting

Testing a TNF-blocking drug to reduce death in HIV and TB meningitis

Tuberculous MeningitisHIV I Infection

Treatments studied

Part of Brain & nervous system, Infections clinical trials.

This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
130 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Be 18 years or older
  • Have HIV infection
  • Have definite or probable TB meningitis
  • Start standard TB meningitis treatment no more than 3 days ago (including anti-TB drugs at standard doses and high-dose dexamethasone)
  • Be able to give consent (you or a close relative) for study participation

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05917340Not yet recruiting· Phase 3
Tested short TB meningitis treatment with stronger follow-up

This trial tests an intensified, shorter treatment plan for TB meningitis (TB in the lining around the brain) in adults, including people with HIV. It may help some patients get better with a structured plan while researchers compare treatment outcomes and safety.

Chennai, Tamil Nadu
NCT04145258Recruiting· Phase 3
Stronger TB treatment for meningitis to reduce deaths

This trial tests if giving a stronger combination of TB drugs for meningitis can save more lives. It's for patients who have been diagnosed with tuberculosis meningitis and have not yet started more than 5 days of TB treatment.

Abidjan
NCT05947890Recruiting· Phase 2
Testing an immune-boosting TB vaccine in people with or without HIV

This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.

Johannesburg, Gauteng
NCT06205589Not yet recruiting· Phase 2
Testing an experimental TB vaccine during treatment

This trial tests whether an experimental vaccine (ID93 + GLA-SE) can improve outcomes in people being treated for drug-sensitive tuberculosis. It is for those newly diagnosed or who have been on standard TB treatment for a few months.

NCT07136987Not yet recruiting· Phase 3
Testing metformin and NAC to help lung recovery after TB

This trial tests two drugs, metformin and N-acetylcysteine, to see if they can help your lungs work better after you finish tuberculosis treatment. You may join if you have active TB with lung damage and are starting standard TB therapy.

NCT06909799Recruiting
NAC to prevent lung damage after TB treatment

This trial tests if taking N-acetylcysteine (NAC) alongside standard TB treatment can help prevent long-term lung problems after tuberculosis. It is for people with moderate to severe TB who already have some reduced lung function.

Fajara, The Gambia

Hear when a new Tuberculous Meningitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.